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TransportersAntimicrobial peptides (AMPs) are at the front-line of host defense during infection and play critical roles both in
reducing themicrobial load early during infection and in linking innate to adaptive immunity. However, success-
ful pathogens have developed mechanisms to resist AMPs. Although considerable progress has been made in
elucidating AMP-resistance mechanisms of pathogenic bacteria in vitro, less is known regarding the in vivo
signiﬁcance of such resistance. Nevertheless, progress has beenmade in this area, largely by usingmurinemodels
and, in two instances, human models of infection. Herein, we review progress on the use of in vivo infection
models in AMP research and discuss the AMP resistance mechanisms that have been established by in vivo
studies to contribute to microbial infection. We posit that in vivo infection models are essential tools for investi-
gators to understand the signiﬁcance to pathogenesis of genetic changes that impact levels of bacterial suscepti-
bility to AMPs. This article is part of a Special Issue entitled: Bacterial Resistance to Antimicrobial Peptides.
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Antimicrobial peptides (AMPs) are small, amphipathic peptides that
attack microbial invaders of eukaryotic hosts (reviewed in [1,2]). AMPs
are considered “host antibiotics” as they are critical components of the
innate host response to infection. Moreover, because they can exert
direct and/or indirect antimicrobial action, they have also been termed
host-defense peptides [3] due to their capacity to link innate immunity
to adaptive immune systems. The efﬁcacy of AMP action in vivo coupled
with the ability of microbes to resist their action can inﬂuence the
microbial population level before adaptive immune responses become
available. The over-arching goal of this review is to highlight seminal
reports that provide important insights into the signiﬁcance of bacterial
AMP-resistancemechanisms during infection, as assessed by vertebrate
and other model systems.
Most AMPs have a net positive charge; by this cationic nature, AMPs
are preferentially attracted to microbial cell surfaces, which are more
negatively charged than eukaryotic cell surfaces. Once associated with
the microbial surface, their amphipathic nature allows AMPs to insert
into a microbe’s cell membrane, disrupting the integrity of the mem-
brane and leading to osmotic lysis of themicrobial cell. This generalized
pathway offers microbes numerous opportunities to develop decreased
susceptibility to AMPs, and bacteria frequently accomplish this by
altering – sometimes subtly – cell envelope structures that impede
AMP binding events.
AMPs are ubiquitous in eukaryotic organisms, fromplants to animals
and invertebrates to mammals. Mammalian AMPs include defensins,
which form β-sheets, and the cathelicidins, which exhibit greater struc-
tural heterogeneity. The defensins contain six Cys residues and form
three intramolecular disulﬁde bonds; defensins are subdivided into α-
and β-defensins by the positions and bonding patterns of their
cysteines. Humans produce six α-defensins, over 30 β-defensins, and
one α-helical cathelicidin, termed LL-37. These cationic AMPs are
expressed primarily in neutrophils, macrophages, epithelial cells, and
specialized secretory cells, such as the Paneth cells of the gut. In phago-
cytes, AMPs reside in granules and contribute to phagolysosomal killing
of engulfed microbes; AMPs are also released by phagocyte degranula-
tion to kill extracellular pathogens. AMPs secreted by epithelial cells
and Paneth cells contribute to the innate barrier defenses against
infection.
In order to survive in eukaryotic hosts, bacterial pathogens have
evolved mechanisms to overcome the antimicrobial activity of AMPs.
They often use systems similar to mechanisms identiﬁed for resistance
to classical antibiotics. In vitro studies utilizing a variety of AMP suscep-
tibility assays and bacterial genetic tools have elucidated a number of
mechanisms bacteria use to thwart AMP activity [4]; examples of bacte-
rial AMP-resistance systems include degradation, target modiﬁcation,
decreased import, and energy-dependent transport.
A full understanding of how bacteria overcome AMP-mediated
attack during infection requires a combination of in vitro and in vivo
studies. In vitro work is critical to understanding the genes, proteins,
andmechanisms involved in AMP resistance; however, the contribution
of these in vitro-established mechanisms to bacterial disease can only
be elucidated in vivo. Here, we review the literature on in vivo studies
that examine the role of AMP resistance mechanisms in bacterial
pathogenesis. We ﬁrst describe the major in vivo models used in these
studies; we then discuss the collective ﬁndings of in vitro and in vivo
research that established AMP resistancemechanismswhich contribute
signiﬁcantly to bacterial disease.For the purposes of this review, we largely conﬁned our focus to
cationic AMPs and to in vivo studies that directly compared parent
strains in vivo with isogenic derivatives in which genes involved in
AMP resistance were inactivated. A number of in vivo studies have
demonstrated the importance to pathogenesis of two-component signal
transduction systems that modulate AMP resistance mechanisms, such
as the extensively-studied PhoPQ system of Salmonella enterica serovar
Typhimurium and other Gram-negative pathogens (recently reviewed
in [5]). However, the regulatory networks governed by these two-
component signal transduction systems include genes not involved in
AMP resistance; thus, the speciﬁc contribution of AMP resistance
in vivo is difﬁcult to discern from mutants affecting the entire regulon.
We have therefore focused this review primarily on mutants carrying
loss-of-function mutations in structural genes involved in AMP resis-
tance mechanisms.
It is ﬁrst, however, necessary to deﬁne what we mean by AMP-
resistance in the context of this review. Accordingly, since minimal
inhibitory concentration (MIC) “breakpoints” typically used for classical
antibiotics to separate sensitive from resistant strains are not easily
determined for AMPs, we will refer to resistance mechanisms as those
that endow bacteria with increased ﬁtness or survivability during infec-
tion. In this regard, it is important to emphasize that somemutations or
gene acquisitions may only have slight inﬂuences (2-4 fold changes) in
bacterial susceptibility to AMPs under laboratory conditions; yet their
inﬂuence in vivo is substantially greater when assessed in an infection
model.
2. In vivo models of AMP resistance mechanisms in pathogenesis
2.1. Human models of infection
To study human pathogens, an ideal in vivo model would be a
human experimental infectionmodel. Of course, concerns such as safety
to the human subjects and transmissibility to the public preclude the
ability to perform human infection experiments with most bacterial
pathogens. However, within limitations imposed for medical and
ethical reasons, a few human experimental infection models are
currently in use. These models provide the ability to accurately recapit-
ulate the kinetics of natural, human disease. Importantly, human
models of infection allow the study of a human pathogen in the context
of the speciﬁc, host-derived pressures with which the pathogen
evolved. One such host-derived pressure is attack by AMPs; as AMP re-
sistance mechanisms are often speciﬁc for certain AMPs, it is beneﬁcial
to examine AMP resistance against the AMPs that pathogen encounters
during infection. Another advantage of human models is that they can
be adapted for testing new therapeutics for treatment of infections or
vaccine candidates for disease prevention.
As with any model, human infection models have limitations. For
subject safety reasons, these models are generally limited to local infec-
tions and to the early stages of disease, with treatment at the onset of
symptoms or discomfort; long-term infections, systemic infections,
and sequelae cannot be safely examined in human volunteers. To en-
sure control of the infection, human models are typically restricted to
one or two well-characterized wild-type bacterial strains, and isogenic
derivatives thereof, that are readily treatable and do not harbor plas-
mids or phages that could transmit genetic material to the host’s micro-
bial ﬂora. Many other aspects of human infection models, such as route
of inoculation and dosage, are far less ﬂexible than in animal models.
Working within these limitations, however, human experimental
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provide important information about the host-pathogen relationship
that is directly relevant to humans. Two such models have been used
to examine the role of AMP resistancemechanisms in human infectious
disease [6,7].
Haemophilus ducreyi is a human-speciﬁc pathogen that causes the
sexually transmitted, genital ulcer disease chancroid as well as a non-
sexually transmitted chronic limb ulceration syndrome [8–10]. Lacking
nonhuman animal models that accurately mimicked human disease,
Spinola et al. developed a human model of H. ducreyi infection in
which healthy, adult volunteers are inoculated in the upper arm and
followed through the papular and pustular stages of disease; for subject
safety reasons, infections are terminated before lesions ulcerate [6,11,
12]. Importantly, this model likely reﬂects early host defense events
during development of both chancroid and chronic limb ulceration
syndrome and allows for testing the importance of presumed virulence
factors. For parent-mutant strain comparisons, each subject is inoculat-
ed with the parent strain on one arm andwith themutant strain on the
other arm; thus, each subject serves as his or her own control. This
human infectionmodelwas used to deﬁne the contribution to virulence
of the Sap transporter, which protects H. ducreyi from AMPs in vitro
(discussed in Section 3.3.2; see also Fig. 1) [13]. This study was the
ﬁrst to establish a role for AMP resistance mechanisms in human
disease.
Neisseria gonorrhoeae, which causes the sexually transmitted infec-
tion gonorrhea, is another human-speciﬁc pathogen for which reliable
nonhuman animalmodelswere historically difﬁcult to establish. Gonor-
rhea causes urethritis in males and cervicitis in females, with ascending
female infections leading to salpingitis, pelvic inﬂammatory disease,
and sterility. Cohen et al. developed a human infection model in
which healthy male volunteers are inoculated intraurethrally with
N. gonorrhoeae and followed until symptoms begin or urinalysis
indicates colonization [7]. It is important to stress that complications as-
sociated with ascending infection preclude the use of women in exper-
imental gonococcal infection. Thus, within the limitations of differences
in the structure, physiology and host defenses in the male vs. female
reproductive tract and how gonococcal virulence factors might function
in these two environments, this human infection model has over the
past twenty years provided important insights regarding gonococcal
pathogenesis during early stages of infection (reviewed in [14]). In the
infection model, parent-mutant comparisons are performed by co-A ΔsapBCParent
Fig. 1. The Sap transporter contributes to virulence of H. ducreyi in human volunteers. (A) Arm
mutant strain 35000HPsapBC (right panel) [79]. Arrows indicate sites of inoculation (outlined b
tant-inoculated sites (right) in this volunteer. Stickers on volunteer arms in photos indicate scal
(B) Pustule formation rates in human volunteers inoculated with parent strain 35000HP and ei
in vivo correlated with the level of LL-37 resistance in vitro [79]. Asterisks indicate signiﬁcant
Spinola.infection with the two strains at a 1:1 ratio and determining the ratio
(reported as a competitive index) of parent to mutant colonies recov-
ered from the host; such co-infections demonstrate the relative ﬁtness
of isogenic mutants compared with wild-type strains in vivo [15].
With respect to AMP-resistance systems, Hobbs et al. recently used
the human gonococcal infection model to determine the contribution
of the lipid A phosphoethanolamine (PEA) transferase, LptA (discussed
in Section 3.1.1), to virulence during human infection; this was the ﬁrst
study to establish electrostatic repulsion of AMPs as a signiﬁcant con-
tributor to human disease [15].
2.2. Nonhuman in vivo models of infection
For most pathogens, no option exists for human experimentation;
researchers rely instead on various nonhuman vertebrate and inverte-
brate models to study pathogenic mechanisms, including the impor-
tance of AMP-resistance systems, in vivo. These models, which we will
refer to collectively as animal models, offer several advantages, includ-
ing the generally lower cost of non-primate animal studies compared
with human studies, the ability to study later stages of infection, and
the ability to choose and even manipulate the genetic background of
the host. Disadvantages of animal infection models include the inability
to study host-restricted aspects of the disease or host response, and the
difﬁculty in establishing the relevance to humans of results obtained in
animals.Within these limitations, however,most bacterial pathogenesis
studies have been performed in animals and have provided a wealth of
information on host-pathogen interactions.
2.2.1. Mouse models of infection
The most widespread animal used to study AMP resistance mecha-
nisms in vivo has been the mouse (Table 1). One advantage of using
mice is the ability to use different routes of inoculation to examine
different stages of disease. The most extensively used in vivo system
for studying bacterial AMP-resistancemechanisms has beenmurine in-
fections with S. Typhimurium, which causes gastroenteritis in humans
and a typhoid fever-like disease in mice. This pathogen may be used
in mice to model typhoid fever, in which S. Typhimurium is ingested
and colonizes the small intestine, including Peyer’s Patches, from
which the organism crosses the gut epithelial barrier, is taken up by
macrophages, and disseminates to the reticuloendothelial system
(RES); in the RES, the bacteria reside and multiply in mesentericPu
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Table 1
AMP resistance mechanisms examined in vivo.
Mechanism of AMP Resistance Organism Virulence Factor(s) In vivo Model(s), route of inoculationa Reference(s)
Electrostatic Repulsion
PEA modiﬁcation of lipid A N. gonorrhoeae LptA Human, male, intraurethral [15]
Mouse, female, intravaginal [15,30]
S. Typhimurium PmrC Mouse, oral and i.p. [35]
PEA modiﬁcation of LOS core S. Typhimurium CptA Mouse, oral and i.p. [35]
PEA modiﬁcation of LPS, ﬂagella, glycans C. jejuni EptC Mouse, oral [34]
Chick, oral [34]
Aminoarabinose modiﬁcation of LPS S. Typhimurium PmrHFIJKLM Mouse, oral and i.p. [17,18]
Mouse, CRAMP−/−, oral [18]
Mouse,MMP7−/−, oral [18]
D-Ala modiﬁcation of lipoteichoic acid Group B Streptococcus DltA Rat, i.p. [42]
Mouse, i.n. and i.v. [42]
L. monocytogenes DltA Mouse, i.v. [45]
S. aureus DltA Mouse, i.v. [41]
Rabbit, i.v. [44]
L-Lys modiﬁcation of cell membrane phosphatidylglycerol S. aureus MprF Rabbit, i.v. [44]
Mouse, i.v. [43]
L. monocytogenes MprF Mouse, i.v. [46]
Galactosamine modiﬁcation of lipid A F. novicida AlmEFG Mouse, subcutaneous [37]
Membrane ﬂuidity/permeability
Lipid A modiﬁed by acylation K. pneumoniae LpxM Mouse, i.n. and i.v. [48]
L. pneumophila Rcp Mouse, i.t. [47]
LPS truncation
LPS core synthesis P. multocida HptA Chicken, i.m. [50]
H. inﬂuenzae, nontypeable LpsA, OpsX, LgtF Mouse, i.n. [51]
B. cenocepacia HldA, HldD Rat, i.t. [49]
B. bronchiseptica Pgm Mouse, i.n. [52]
Surface modiﬁcation
LPS biosynthesis S. Typhimurium Pgm Mouse, i.v. [53]
modiﬁcation of unidentiﬁed surface structures Y. pestis PgmA Mouse, i.n. and i.v. [25]
Phosphate modiﬁcation of LPS core S. Typhimurium WaaP Mouse, oral, i.p., and i.v. [54]
Phosphocholine modiﬁcation of LPS core P. multocida PcgC Chicken, i.m. and i.t. [55]
Transport
Efﬂux Pump N. gonorrhoeae MTR Mouse, female, intravaginal [62,64]
V. cholerae VexAB Mouse, infant, oral [65]
Uptake transport E. chrysanthemi SapABCDF Potato tuber, injection [77]
Chicory leaves, injection [82]
H. ducreyi SapA Human, cutaneous [13]
SapBC Human, cutaneous [79]
H. inﬂuenzae, nontypeable SapA Chinchilla, i.n. and transbullar [72,75]
SapD Chinchilla, i.n. and transbullar [78]
S. Typhimurium SapCDF, SapDF Mouse, oral and i.p. [73]
YejABDF Mouse, oral and i.p. [90]
AMP binding proteins
Bind AMP, prevent AMP from reaching cell membrane Group B Streptococcus PilB Mouse, i.p. and i.v. [89]
Group A Streptococcus SIC Mouse, i.p. [91]
Unclear
Ferrous iron-binding protein S. Typhimurium Omb Mouse, oral and i.p. [92]
a Routes of inoculation: i.m., intramuscular; i.n., intranasal; i.p., intraperitoneal; i.t., intratracheal; i.v., intravenous.
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orally administered infectionswith those administered intraperitoneal-
ly, inwhich bacteria are directly taken up bymacrophages, investigators
can determine the contribution of speciﬁc virulence factors to early or
late stages of disease. This approach showed that Mig-14, a regulator
of AMP resistance, is dispensable for initial gut colonization but is
required for survival in the RES [16]; in contrast, electrostatic repulsion
by 4-aminoarabinose (Ara4N) (discussed in Section 3.1.1) was found to
be important for initial infection of the gut but not for later stages of
disease [17,18].
Another advantage ofmousemodels is the ability to use a genetically
deﬁned host. As with routes of inoculation, the host genetics can be var-
ied to examine different stages of disease. For example, many mouse
strains used in models of S. Typhimurium infection carry a mutation in
Nramp1 that renders the mice highly susceptible to infection; thus,
these mice typically succumb to infection before adaptive immune re-
sponses can develop. In contrast, mice with a wild-type Nramp1 gene
product can become persistently infected with S. Typhimurium, but
with little to no disease, for up to 1 year. Thus, Nramp1+/+ mice can
be used to study long-term persistence of S. Typhimurium infection[19]; this model was used to demonstrate the importance of Mig-14-
mediated AMP resistance in establishing the persistent carrier state of
S. Typhimurium infection [20].
The availability of knockout mice lacking speciﬁc genes is an invalu-
able tool for understanding the host side of the host-pathogen relation-
ship. Two knockout mouse strains are available that affect the repertoire
of murine AMPs. Mice express the cathelicidin-related AMP (CRAMP), a
homolog of LL-37; CRAMP−/−mice are hyper-susceptible to several bac-
terial infections, including a subcutaneous anthrax infection model [21]
and Group A streptococcal skin and soft tissue infections [22]. Mouse in-
testinal crypts contain α-defensins called cryptdins, which are activated
upon cleavage by matrix metalloprotease 7 (MMP7, Matrilysin).
MMP7−/− mice cannot activate intracellular cryptdins; however,
cryptdins secreted into the intestinal lumen are activated by other lumen-
al proteases.MMP7−/−mice are colonized to a greater extent by E. coli
and are more susceptible to the lethal effects of S. Typhimurium infection
[23]. Interestingly, when CRAMP−/−mice were challenged with Ara4N-
deﬁcient S. Typhimurium, no greater attenuation was observed than in
wild-type mice [18]; these studies showed that CRAMP alone is not a
major mediator of clearance of Ara4N-deﬁcient S. Typhimurium.
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animals expressing human genes. For example, transgenic mice ex-
pressing the human α-defensin HD-5 have helped to understand the
importance of this AMP in combating S. Typhimurium infection and
the contributions of resistance mechanisms to disease progression
[24]. To be sure, additionalmouse strainswill be developed in the future
for testing host and bacterial factors thatmodulate the efﬁcacy of the in-
nate immunity arm of host defense, which includes AMPs.
2.2.2. Other in vivo models
In addition to humans and mice, a variety of less common in vivo
models have been used to examine the role of AMP resistance mecha-
nisms in bacterial disease (Table 1). Several of these involve natural
hosts or long-establishedmodels of speciﬁc diseases. Among the natural
host models used in understanding AMP resistance mechanisms is the
ﬂea model of Yersinia pestis infection. Y. pestis, the causative agent of
plague, is a vector-borne disease that primarily infects rodents and is
transmitted by ﬂeas. As insects produce AMPs, Felek et al. examined
the effects of the AMP resistance gene pgmA (discussed in Section 3.2)
on the survival of Y. pestis in ﬂeas and the bacterium’s transmission
from ﬂeas to mice [25]. Another natural host model is the chicken,
which has been used to examine AMP resistance mechanisms of zoo-
notic pathogens, such as Campylobacter jejuni, a common colonizer of
poultry and cause of food-borne gastroenteritis in people, and
Pasteurella multocida, which causes fowl cholera in many avian species
and can cause severe animal bite-related wound infections and oppor-
tunistic infections in humans. Other in vivo models that have been
used to study AMP resistance mechanisms in a pathogen’s natural
host include oysters, as a model for the marine pathogen Vibrio
splendidus, and potatoes and witloof chicory leaves, which have been
used to study the plant pathogen Erwinia chrysanthemi (recently
renamed Dickeya dadantii). Although the extensive array of tools used
with mice is not available in these models, they do have the advantage
of being the natural setting for the pathogen of interest.
Although not a natural host, the chinchilla has long been used as a
model for studying otitismedia. The chinchillamodel iswell established
and allows infection with several of the most common causes of inner
ear infections, including Haemophilus inﬂuenzae. As will be discussed
in Section 3, all of these models have been used to examine the effects
of AMP resistance mechanisms on virulence.
3. Antimicrobial peptide resistance mechanisms that contribute to
bacterial disease
What havewe learned from these in vivo infectionmodels about the
importance of AMP resistance mechanisms with respect to bacterial
pathogenesis? A combination of in vitro and in vivo studies have de-
ﬁned an array of AMP resistance mechanisms; most of these fall mech-
anistically into a few categories. The best deﬁned AMP resistance
mechanisms directly shown to contribute to virulence in vivo are mod-
iﬁcation of cell surface structures with positively charged moieties for
electrostatic repulsion of cationic AMPs and the use of molecular trans-
porters to pump AMPs away from the cell membrane. In addition to
these mechanisms, several virulence factors have been deﬁned that af-
fect AMP resistance and virulence by less well-understood mechanisms
that primarily involve modiﬁcations to surface structures.
3.1. Electrostatic repulsion
The bacterial cell surface is typically more negatively charged than
eukaryotic cell surfaces; cationic AMPs are thus more highly attracted
to bacterial cells than to the cells of the host. By adding positively
charged molecules to the bacterial surface, a wide variety of bacterial
pathogens render their cell surfaces less negatively charged and thus
less attractive to cationic AMPs. In Gram-negative bacteria, electrostatic
repulsion can be elicited by modifying surface structures with PEA orAra4N. In Gram-positive bacteria, a similar result is achieved by adding
D-Ala residues to cell wall polymers or lysine residues to membrane
phospholipids. The contribution to virulence has been demonstrated
in vivo for each of these mechanisms of electrostatic repulsion.3.1.1. Gram-negative electrostatic repulsion mechanisms
One of the most thorough studies of the contribution of electrostatic
repulsion to virulence has been performedwith the human-speciﬁc path-
ogen N. gonorrhoeae. The lipooligosaccharide (LOS) of N. gonorrhoeae is
decorated with PEA on its lipid A and core sugars [26]. While the core
sugar PEA modiﬁcations have only minor effects on AMP resistance, loss
of the lipid A PEA transferase, LptA, signiﬁcantly impairs the organism’s
ability to survive attack by AMPs [26]. The contribution of LptA to patho-
genesis was recently demonstrated using two in vivo models of disease
[15], namely the human male and female mouse experimental systems.
In the human challenge model of N. gonorrhoeae infection (described in
Section 2.1), the lptAmutant was outcompeted ~ 100-fold by its isogenic
wild-type parent strain, demonstrating the importance of lipid A-PEA
modiﬁcation to N. gonorrhoeae infection in humans [15].
The humanmodel of N. gonorrhoeae infection is limited to male vol-
unteers, because of the risks associatedwith ascending gonorrhea infec-
tions in women. However, the organism’s pathogenesis differs between
themale urethra and the female reproductive tract [27]. To study female
gonococcal disease, a mouse model was developed by A. Jerse and col-
leagues inwhich 17β-estradiol treatment, combinedwith streptomycin
to reduce the level of competing commensal bacteria in the reproduc-
tive tract, renders female mice susceptible to vaginal infection [28,29].
Thismodel is a highly useful tool that allows investigators to test the sig-
niﬁcance of presumed gonococcal virulence factors during infection and
draw inferences about pathogenesis, despite differences between mice
and humans,whichmay not be fully appreciated by the sole use of com-
mon laboratory procedures involving test tubes or tissue culture sys-
tems. In brief, the model allows colonization of the female mouse
genital tract, with recovery of bacteria from the vagina and cervix;
ascending infection is seen in 17-20% of infected mice, mimicking the
ascending reproductive tract infections in women. A purulent neutro-
phil response develops, similar to that in symptomatic women.
With this estradiol-treated mouse model, Hobbs et al. and Packiam
et al. examined the role of LptA in female reproductive tract disease
[15,30]. Although single strain infection experiments showed little
difference between the parent and isogenic lptA mutant strains for
colonization, co-infection experiments demonstrated that the lptAmu-
tant was signiﬁcantly less ﬁt than the parent strain in the female
mouse reproductive tract [15,30]. Interestingly, however, relative to
the parent strain, the lptAmutant also induced a much weaker host in-
ﬂammatory response, suggesting an immunostimulatory role for LptA
in addition to its protective function [30]. A similar study is now under-
way (M. Hobbs, personal communication) in the human male infection
model system. Nevertheless, based on the similar results obtained in the
co-infection models, we posit that (at the very least for gonococci), the
mousemodel developed by A. Jerse has been validated for use in studies
dealing with the in vivo signiﬁcance of bacterial AMP-resistance
mechanisms.
Unlike LptA inN. gonorrhoeae, whose only known substrate is lipid A,
the LptA homolog in C. jejuni, EptC, modiﬁes several diverse substrates,
including lipid A, LOS core heptose I, the ﬂagellar subunit protein FlgG,
and N-linked glycans that decorate periplasmic proteins [31–34]. Loss
of eptC increases bacterial sensitivity to polymyxin B and several
human and avian AMPs, decreases motility, and lessens TLR4-MD2
complex-mediated responses [34]. In vivo, EptC is needed to colonize
the gastrointestinal tracts of chickens and mice, suggesting an impor-
tant role for PEA modiﬁcation in both avian commensalism and
mammalian disease [34].
In addition to PEA, a number of Gram-negative pathogens modify
their lipopolysaccharide (LPS) with Ara4N. In vitro studies have
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resistance. The best studied example of the in vivo contribution of
Ara4N to virulence is in S. Typhimurium, in which Ara4N is generated
and added to LPS by the products of pmrE and the pmrHFIJKLM operon.
Using a pmrFmutant thatwaspolar on the rest of the operon, Gunnet al.
showed that the pmrF-M genes are not required for S. Typhimurium
survival in mice when administered intraperitoneally but are required
when the organism is administered orally [17,18]; thus, the Ara4Nmod-
iﬁcation likely protects S. Typhimurium fromhost defenses encountered
in the intestine but not in macrophages that engulf the bacteria in the
peritoneum. Interestingly, despite the in vitro connection between
Ara4N modiﬁcation and resistance to polymyxin B, virulence studies
in knockoutmice showed that the attenuation of Ara4N-deﬁcient bacte-
ria was not due to CRAMP [18]. However, the Ara4N-deﬁcient bacteria
induced an altered innate immune response compared with wild-type
S. Typhimurium [18].
S. TyphimuriumLPS is alsomodiﬁedwith PEAmoieties on the lipid A
and core. These modiﬁcations are mediated by PEA transferases PmrC,
which modiﬁes lipid A, and CptA, which modiﬁes the core Heptose I
sugar. In mice inoculated either orally or intraperitoneally, neither the
pmrC nor cptAmutant was attenuated for infection in single strain inoc-
ulation studies, norwas eithermutant outcompeted by theparent strain
in vivo [35]. However, a pmrC cptA double mutant used in co-infection
with the isogenic parent strain showed amodest but statistically signif-
icant impairment [35]. Thus, in S. Typhimurium, PmrC and CptA provide
onlyminor contributions to virulence; rather, Ara4Nmodiﬁcation of LPS
appears to be the dominantmechanism of electrostatic repulsion in this
pathogen. Side-by-side comparisons of polymyxin B sensitivities con-
ﬁrmed that Ara4N modiﬁcation contributes more than PEA modiﬁca-
tion to AMP resistance in S. Typhimurium [36]. In contrast, PEA
modiﬁcations contribute more to virulence of N. gonorrhoeae and
C. jejuni, which do not modify their LOS with Ara4N.
In addition to PEA and Ara4N, Gram-negative pathogens can use
other amine-containing surfacemodiﬁcations to induce electrostatic re-
pulsion. Francisella noivicida has an unusual outer membrane, in which
70% of the lipid A lacks KDO, core sugars, and O antigen; these “free”
lipid A molecules are modiﬁed with galactosamine at the 1-phosphate
position [37]. The deacetylase NaxD is required for this galactosamine
modiﬁcation; a naxDmutant ismore negatively charged than its isogen-
ic parent, more sensitive to polymyxin B, and less able to replicate in
macrophages [37]. In vivo, the naxDmutant was less ﬁt than the parent
strain and signiﬁcantly attenuated for lethality in mice [37]. Similarly,
Vibrio cholerae, which causes the diarrheagenic disease cholera, adds
Gly and diglycine moieties to its lipid A; although not examined
in vivo, this modiﬁcation signiﬁcantly enhanced the organism’s resis-
tance to polymyxin B in vitro [38]. Interestingly, theV. cholerae genes in-
volved in Gly addition to lipid A, almEFG, bear structural and functional
homology to those involved in addition of D-Ala to Gram-positive cell
wall components (discussed in Section 3.1.2), thus mechanistically
bridging the divide between Gram-negative and Gram-positive cell
wall modiﬁcations that exert electrostatic repulsion [38,39].
3.1.2. Gram-positive electrostatic repulsion mechanisms
Addition of amino acids to the Gram-positive cell wall increases the
surface charge and confers protection from AMPs in several important
pathogens. In Staphylococcus aureus (and other Gram-positive patho-
gens includingClostridium difﬁcile and Listeria monocytogenes), products
of the dltABCD operon mediate addition of D-Ala esters to cell wall
lipoteichoic acid and confer protection from neutrophil α-defensins
HNP1-3 and from nonoxidative killing by human neutrophils [40,41].
In a mouse model of S. aureus sepsis, a dltABCD mutant was impaired,
relative to its isogenic parent, in disease progression, with signiﬁcantly
reduced rates of septic arthritis and mortality and reduced bacterial
load in the kidneys [41]. Similarly, a dltA mutant in Streptococcus
agalactiae, or Group B Streptococcus (GBS), which causes invasive infec-
tions, shows increased sensitivity to human α-defensins and to killingby human neutrophils and macrophages [42]. In vivo, the GBS dltA
mutant exhibited a signiﬁcantly higher LD50 in neonatal rats [42]. In
mouse models of GBS disease, intranasal inoculation with wild-type
bacteria led to pneumonia, and intravenous inoculation induced bacter-
emia, colonized the brain, and caused meningitis; the GBS dltAmutant
was cleared from lungs too quickly to cause pneumonia andwas unable
to survive in the bloodstream or colonize the brain [42]. Together, these
studies demonstrate the importance of D-Ala esteriﬁcation of
lipoteichoic acid to invasive disease by Gram-positive cocci.
Another mechanism of electrostatic repulsion in Gram-positive bac-
teria is addition of positively charged L-Lys to cell membrane
phosphatidylglycerol, which is mediated by the multiple peptide resis-
tance factor MprF. Deletion ofmprF renders S. aureusmore sensitive to
cationic AMPs and to nonoxidative killing by human neutrophils [43];
in a mouse model of sepsis, themprFmutant was similar to the dltABCD
mutant in being attenuated for lethality, induction of septic arthritis,
and colonization of kidneys, thus conﬁrming a role for electrostatic re-
pulsion in invasive S. aureus disease [43]. The in vivo contributions of
these mechanisms to S. aureus virulence were directly compared in a
rabbit model of infective endocarditis. In this model, sterile vegetations
are artiﬁcially induced on the aortic valve, followedby intravenous inoc-
ulation with S. aureus strains [44]. Relative to their isogenic parent
strain, both dltA and mprF mutants were more rapidly cleared from
the bloodstream and impaired in their level of colonization of cardiac
vegetations; however, only the dltA mutant was impaired for subse-
quent spread to the kidneys and spleen; the mprF mutant and parent
strain colonized these organs to similar extents [44]. Thus, while both
mechanisms contribute to invasive disease, D-Ala esteriﬁcation of
lipoteichoic acid appears to play a greater role in systemic disease
caused by S. aureus.
Electrostatic repulsion of cationic AMPs also contributes to virulence
of the intracellular pathogen L. monocytogenes. Both dltABCD-mediated
D-Ala modiﬁcation of lipoteichoic acid and mprF-mediated L-Lys addi-
tion to phosphatidylglycerol contribute to cationic AMP resistance
in vitro [45,46]. In separate studies utilizing a mouse model of invasive
listeriosis, a dltA mutant was severely attenuated for survival in the
bloodstream, liver and spleen and had a 10,000-fold increase in LD50
[45], and an mprF mutant was similarly attenuated for survival in the
liver and spleen [46]. Thus, both intracellular and extracellular patho-
gens enhance their virulence by electrostatic repulsion.3.2. Other surface modiﬁcations
In addition to themechanisms of electrostatic repulsion described in
Section 3.1, numerous surface modiﬁcations, primarily of the Gram-
negative cell wall, have been found to affect AMP resistance, though
the exact mechanisms of action are not always clear. Resistance to cat-
ionic AMPs in several pathogens is associated with speciﬁc acylation
events on lipid A. The lipid A palmitoyltransferase PagP adds palmitate
to lipid A and enhances cationic AMP resistance, presumably by increas-
ing the hydrophobicity of the outer membrane to prevent AMPs from
translocating across themembrane into the periplasm. The PagP homo-
log Rcp is associated with virulence in Legionella pneumophila, in which
co-infection of wild-type and isogenic rcpmutant revealed a ﬁtness de-
fect in the rcpmutant for colonizing the lungs [47]. Similarly, an lpxM
mutant of Klebsiella pneumoniae, which expresses a pentaacylated
lipid A, had increased sensitivity to α-helical cationic AMPs and was at-
tenuated inmice for colonization of the lungs and spleen [48]. Although
no in vitro growth defect was identiﬁed in these acylation mutants, the
increased permeability of the outer membrane couldmake themutants
more vulnerable to complement or osmotic pressures in the host envi-
ronment independent of AMP activity. Similarly, genes affecting synthe-
sis of the core oligosaccharide of LPS or LOS are correlated with AMP
resistance and virulence in several pathogens (Table 1) [49–51]. How-
ever, truncation of the core and loss of O-Ag likely impair bacterial
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contribution of AMPs to the attenuation of core-truncated mutants
can be difﬁcult to ascertain.
Phosphoglucomutase (Pgm) is correlated with AMP resistance and
virulence in several pathogens. PGM interconverts glucose-1-
phosphate and glucose-6-phosphate and plays a role in production of
nucleotide sugars used in biosynthesis of the LPS core. A pgm mutant
in Bordetella bronchiseptica lacks O-Ag and expresses a truncated core
oligosaccharide lacking hexoses [52]. This mutant showed increased
sensitivity to oxidative stress and an insect AMP; in a mouse model of
respiratory tract infection, the pgmmutant was cleared from lungs in
4 days while the isogenic parent caused disease that persisted for
7 weeks [52]. An S. Typhimurium pgmmutant expressed full LPS core
and a truncated O-Ag; in vivo, the pgmmutant was attenuated for colo-
nization of liver and spleen [53]. Interestingly, a Y. pestismutant lacking
Pgm expressed wild-type LPS yet lost AMP resistance, indicating that
Y. pestis Pgm may affect a surface structure other than LPS; unlike pgm
mutants in other bacteria, the Pgm-deﬁcient Y. pestis strain was fully
virulent in mouse and ﬂea models of infection [25]. Thus, the contribu-
tion of Pgm to surface structures and to virulence varies substantially
among pathogens.
Additional LPS modiﬁcations that enhance AMP resistance and viru-
lence includemodifying core sugarswith phosphate or phosphocholine.
Even though phosphorylation enhances the negativity of the cell
surface, phosphorylation of the LPS core is associated with polymyxin
B resistance in S. Typhimurium. A S. Typhimurium mutant lacking the
sugar kinase WaaP generates full length LPS but lacks one heptose,
phosphates on the remaining heptoses, and PEA on heptose I [54].
This waaPmutant had increased sensitivity to polymyxin B in vitro; in
mousemodels of Salmonella infection, thewaaPmutant was attenuated
for lethality and rapidly cleared from the liver and spleen, regardless of
the route of inoculation [54]. P. multocida causes veterinary diseases,
including fowl cholera in poultry. P. multocida modiﬁes its LPS with
phosphocholine, which increases its resistance to the chicken AMP
fowlicidin-1 [55]. A phosphocholine-deﬁcient mutant was unable to
competewith the isogenic parent strain in a chickenmodel of fowl chol-
era; inoculation with the mutant alone caused disease but required a
much longer time frame before symptoms appeared, indicating that
phosphocholine enhances but is not required for virulence in chickens
[55].
3.3. Transport-mediated AMP resistance
3.3.1. Efﬂux pumps
Efﬂux pumps protect bacteria by transporting harmful host-derived
or other exogenous substances out of the cell (reviewed in [56]). In
medically relevant pathogens, efﬂux pumps represent a major mecha-
nism of antibiotic resistance. Additionally, efﬂux pumps of several path-
ogens are able to remove host-derived cationic AMPs. The best-studied
example of an efﬂux pump mediating AMP resistance is the multiple
transferable resistance (MTR) transporter ofN. gonorrhoeae that confers
protection against structurally hydrophobic antimicrobial agents [57].
The MTR transporter is a member of the resistance-nodulation-
division (RND) family of Gram-negative efﬂux pumps and comprises
three proteins: MtrD is an inner membrane transporter energized by
the proton motive force across the cell membrane; MtrE forms an
outer membrane channel; and MtrC is a periplasmic membrane fusion
protein that stabilizes the MtrD-MtrE complex to form a transporter
that crosses the entire cell wall [58–60]. Studies with the E. coli RND
transporter AcrAB-TolC indicated that these transporters can remove
substrates from the cytoplasm, periplasm, and inner membrane [61].
In N. gonorrhoeae, the MTR transporter is required for LL-37 resistance
in vitro [57]; the pump also helps gonococci resist the antimicrobial ac-
tion of progesterone and bile salts.
The role of MTR in pathogenesis was examined using the estradiol-
treated mouse model of N. gonorrhoeae infection (discussed inSection 3.1.1) [62]. In this model, a mutant lacking MtrD and MtrE was
able to colonize mice, but the amount of recoverable bacteria was
much lower than the parent strain [62]. These data were the ﬁrst to
demonstrate a role for an RND efﬂux pump in a genital tract infection.
Subsequent in vivo studies withmutants lacking transcriptionally regu-
latory proteins or harboring cis-acting mutations that control expres-
sion of the mtrCDE operon revealed that mutations impacting
promoter use or loss of the repressor MtrR could increase gonococcal
ﬁtness during infection [63]. In contrast, loss of a transcriptional activa-
tor (MtrA) decreased in vivo ﬁtness of gonococci [64]. Given the similar
results of lptA-positive and –negative gonococci in the humanmale and
female mouse models of infection [15], it is likely that the presence and
levels of theMTR efﬂux pump are important during human infection, as
the pumpwould promote bacterial survival by exporting LL-37 (andpo-
tentially other host antimicrobials).
V. cholerae encodes six RND efﬂux transporters; Bina et al. sought to
identify the role of these transporters in V. cholerae AMP resistance and
virulence. They found that only one RND transporter, VexAB-TolC, con-
ferred resistance to the cationic AMP polymyxin B. Like the
N. gonorrhoeaeMTRsystem, theVexAB systemalso conferred protection
against detergents and other hydrophobic agents in V. cholerae [65]. In
an infant mouse model of cholera, a peroral coinfection of wild-type
and vexBmutant V. cholerae strains showed that the vexB mutant was
outcompeted by its isogenic parent strain for survival in the small intes-
tine [65]. Together, the N. gonorrhoeae and V. cholerae studies demon-
strate that RND transporters enhance the in vivo ﬁtness of pathogenic
bacteria in multiple organ systems and correlate that ﬁtness advantage
with resistance to AMPs.
In vitro studies showed that an MTR-like RND efﬂux transporter in
Neisseria meningitidis conferred resistance to polymyxin B, and an RND
efﬂux transporter in H. ducreyi conferred resistance to LL-37, HBD-2,
and HBD-3 [66,67]. Although no in vivo studies were performed with
isogenic mutants in these transporters, the data suggest that RND
pumps may represent a widespread Gram-negative mechanism of
AMP resistance.
Gram-positive pathogens also produce efﬂux pumps, although the
correlation between active efﬂux and cationic AMP resistance is less
well established. One study examining S. aureus isolates correlated the
presence of the qacA gene, which encodes an efﬂux pump of the major
facilitator superfamily, with resistance to a cationic, platelet-derived
AMP; however, subsequent studies by the same group demonstrated
that QacA-mediated AMP resistance was independent of QacA’s efﬂux
activity [68,69]. Thus, a deﬁnitive role in pathogenesis for Gram-
positive bacteria by efﬂux of AMPs during infection has yet to be
established.
3.3.2. Uptake transporters
In addition to efﬂux pumps, uptake transporters can confer resis-
tance to cationic AMPs. The sensitive to antimicrobial peptides (Sap)
transporter is a peptide uptake transporter closely related to dipeptide
permease (Dpp) and oligopeptide permease (Opp) uptake transporters
that bring small peptides into the cytoplasm for degradation or
recycling [70,71]. The Sap transporter is expressed in many pathogens
of the Gammaproteobacteria class, including the Enterobacteriaceae
and Pasteurellaceae. The pentameric transporter consists of a periplas-
mic solute binding protein, SapA, which binds certain cationic AMPs,
two inner membrane permease proteins, SapB and SapC, which form a
channel for transport, and two cytoplasmic ATP-binding cassette pro-
teins, SapD and SapF, that energize the transporter [71,72].
The Sap transporter was ﬁrst identiﬁed in S. Typhimurium and
shown to confer protection against the model AMP protamine and
crude extracts from human neutrophils, which contain LL-37 and the
α-defensins human neutrophil peptide (HNP)-1, HNP-2, and HNP-3
[71,73]. Transposon mutants affecting the sapCDF genes had a signiﬁ-
cantly higher LD50 than the parent strain, whether delivered orally or
by the intraperitoneal route, in a mouse model of typhoid fever [73].
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human pathogens, including E. coli, H. ducreyi, H. inﬂuenzae, and Proteus
mirabilis, and the plant pathogen E. chrysanthemi [13,74–77]. In vitro
studies in all these pathogens demonstrate that the Sap transporter con-
tributes to AMP resistance; however, the speciﬁcity of AMPs
transported by Sap varies amongpathogens. For example, the Sap trans-
porter of nontypeableH. inﬂuenzae (NTHI) is highly effective against the
human cathelicidin LL-37 as well as human and chinchilla β-defensins,
while the Sap transporter of H. ducreyi protects against LL-37 but has
no effect on human α- or β-defensins, and the S. Typhimurium Sap
transporter is ineffective against a rabbit defensin [13,73,75,78,79]. Sim-
ilarly, the S. Typhimurium Sap transporter conferred protection against
protamine, but the V. ﬁscheri and E. chrysanthemi Sap transporters had
no effect on protamine [73,77,80].
The importance of the Sap transporter in vivo has been established
in several pathogens. In H. ducreyi, two studies examined the contribu-
tions to AMP resistance and virulence of the periplasmic solute binding
protein SapA and the inner membrane SapBC channel. A nonpolar sapA
mutant showed increased sensitivity to LL-37 compared with the iso-
genic parent strain [13], and a nonpolar sapBCmutant was signiﬁcantly
more sensitive to LL-37 than either the isogenic parent strain or the sapA
mutant [79]. These data suggest that the periplasmic component, SapA,
is not absolutely required for transport activity across the SapBC chan-
nel. In vivo studies with the human model of H. ducreyi infection simi-
larly showed that the sapA mutant was partially attenuated for
virulence, as measured by the rate of pustule formation at inoculated
sites; by the same criteria, the sapBCmutantwas fully attenuated for vir-
ulence (Fig. 1). Thus, the levels of attenuation in vivo directly correlated
with the level of LL-37 sensitivity in vitro [79]. Thesewere the ﬁrst stud-
ies to establish that a bacterial AMP resistance mechanism contributes
to human infectious disease.
Mason and colleagues examined the contribution to virulence of Sap
transporter components in NTHI during middle ear infections in the
chinchilla model of otitis media. Mutations in sapA or sapD rendered
NTHI signiﬁcantly impaired for colonization of the nasopharynx and
middle ear [75,78]. In co-infection studies between either the sapA or
sapD mutant and the isogenic parent strain, neither mutant was able
to compete with the wild-type strain, although the sapD mutant was
clearedmore rapidly than the sapAmutant in competitionwith the par-
ent strain [75,78]. In vitro studies show that, in addition to transporting
AMPs, the NTHI Sap transporter imports heme into the cell [81]. The
in vivo importance of the AMP transport activity of NTHI Sapwas inves-
tigated by pretreating chinchillas with neutralizing antibody against
chinchilla β-defensin-1 (cBD-1), followed by co-infection with wild-
type and sapA mutant NTHI strains. With cBD-1 neutralized, the sapA
mutant no longer showed a ﬁtness defect relative to the wild-type
strain; these data conﬁrmed that the Sap transporter protects against
AMPs in vivo [72].
The contribution of the Sap system to bacterial virulence extends be-
yondmammalianpathogens, as evidenced by studies in E. chrysanthemi,
which causes soft rot diseases in many agricultural crop plants. In vivo
studies with potato tubers and witloof chicory leaves demonstrated
that a sapABCDF mutant caused signiﬁcantly less rot than its isogenic
parent; in competitive infections, the sapABCDF mutant was less ﬁt
than the parent strain [77,82]. In vitro, the sapABCDFmutantwas hyper-
sensitive to the plant-derived AMPs snakin-1 and α-thionin but were
unaffected by a potato-derived defensin or protamine [77].
Interestingly, in vivo studies of a Sap transporter in the symbiotic,
bioluminescent bacterium Vibrio ﬁscheri demonstrated that the trans-
porter plays a signiﬁcant role in colonizing the light organ of the bacte-
rium’s host, the Hawaiian bobtail squid (Euprymna scolopes); however,
the transporter has no apparent role in protectingV.ﬁscheri from cation-
ic AMPs [80]. These results suggest that the Sap transporter may have
evolved a different function for this host-symbiont relationship than
for the host-pathogen relationship. However, of the AMPs tested in
this study, none was from the host squid, and only salmon-derivedprotamine was of marine origin [80]; the possibility remains that the
V. ﬁscheri Sap transporter is speciﬁc for AMPs derived from Euprymna
or other marine animals.
3.4. Other mechanisms of AMP resistance
Proteolysis of AMPs is a fairly common mechanism of AMP resis-
tance [83–86]; yet, few studies have shown a direct correlation between
AMP resistance and the in vivo contribution of a protease to virulence.
The outer membrane protein OmpT is the prototypical member of the
so-called omptin family of cell surface proteases, which are expressed
bymanymembers of the Enterobacteriaceae. OmpT in E. coli and several
other pathogens has been shown to cleave LL-37 and other AMPs; how-
ever, most omptin proteases have multiple host substrates. For exam-
ple, the omptin Pla of Y. pestis cleaves plasminogen, and other factors
involved in coagulation and ﬁbrinolysis, as well as Fas ligand and LL-
37 [87,88]. Pla has long been recognized as an important virulence de-
terminant in the spread of Y. pestis during infection; however, its multi-
ple substrates makes determining the speciﬁc role of LL-37 degradation
in virulence difﬁcult.
Streptococcus pyogenes, or GroupA Streptococcus (GAS), andGBS ex-
press surface or secreted proteins that bind cationic AMPs, preventing
their interaction with the cell membrane. GBS expresses a pilus whose
major subunit, PilB, protects the organism from cationic AMPs including
LL-37, murine CRAMP, and polymyxin B; ectopic expression of pilB con-
fers a similar AMP resistance proﬁle to the nonpathogenic, AMP-
sensitive Lactococcus lactis [89]. The pilB-expressing L. lactis strain dem-
onstrated signiﬁcantly increased binding to LL-37, suggesting that PilB
mediates AMP resistance by binding AMPs and preventing their activity
against the bacterial cell [89]. In a mouse model of bloodstream infec-
tion, the pilB mutant was attenuated for survival in the bloodstream
and was signiﬁcantly outcompeted by its isogenic parent strain in co-
infection experiments; the pilBmutant was also signiﬁcantly less lethal
to mice inoculated by the intraperitoneal route [89]. pilB expression in
L. lactis caused this nonpathogen to induce mortality in mice with an
LD50 similar to the parental GBS strain [89].
4. Conclusions
In vivomodel systems are powerful tools for establishing the impor-
tance of AMP resistance mechanisms to bacterial disease processes. As
exempliﬁed by the murine model of S. Typhimurium, in vivo infection
models can also elucidate speciﬁc organs or stages of disease in which
an AMP resistance mechanism is critical. One limitation of in vivo stud-
ies, however, is that the exact cause of decreased ﬁtness of a loss-of-
function mutant can be difﬁcult to establish in vivo. Transporters and
proteases often have additional substrates, and surface modiﬁcations
may affect interactions between the bacterial surface and host compo-
nents other than AMPs. Studies directly conﬁrming that loss-of-ﬁtness
is due to the activity of an AMP, such as by use of a neutralizing anti-
AMP antibody, are very few. Nevertheless, as discussed in this review,
strong correlations have been established in many model systems be-
tween AMP sensitivity of a loss-of-functionmutant in vitro and reduced
ﬁtness or virulence in vivo. Moreover, such in vivo studies unequivocal-
ly establish the important role of AMPs in the host innate immune bar-
rier to bacterial infection.
As AMPs represent an ancient component of host resistance to infec-
tion, and microbes have likely co-evolved with human AMP producers,
it is not surprising that successful pathogens have developed mecha-
nisms to resist their action during infection. While numerous mecha-
nisms of AMP-resistance have been identiﬁed and can be studied with
great rigor under laboratory conditions, formal testing of the signiﬁ-
cance of resistance during human infections can only be done using
model systems of infection. While organ and cell culture systems can
provide valuable insights, they cannot fully replicate the environment
in which microbe-AMP interactions occur; as such, whole models are
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models of infection have limitations, we nevertheless conclude, as
supported by recent results from human infection models, that AMP-
resistance systems can profoundly impact the fate of bacteria during
infection. As the overall AMP research ﬁeld moves forward it is, howev-
er, fair to ask: why are whole animal systems, including humans, need-
ed for AMP-resistance studies? Apart from providing important
information regarding bacterial pathogenesis and host defense, the
models also allow for testing new therapeutics thatmight be inﬂuenced
by AMP-resistance systems. Moreover, attempts to cripple AMP-
resistance systems might be a new strategy to augment host defense.
The efﬁcacy of new therapeutic approaches that must by-pass or target
AMP-resistance will require an intact living system such as those
described herein.
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